Article info
PDFOriginal research
Intergenerational monitoring in clinical trials of germline gene editing
- Correspondence to Dr Bryan Cwik, Philosophy, Portland State University, Portland, OR 97201, USA; bcwik{at}pdx.edu
Citation
Intergenerational monitoring in clinical trials of germline gene editing
Publication history
- Received June 12, 2019
- Revised August 14, 2019
- Accepted August 21, 2019
- First published August 31, 2019.
Online issue publication
February 21, 2020
Article Versions
- Previous version (21 February 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Ethical issues raised by intergenerational monitoring in clinical trials of germline gene modification
- A brief and personal history of ‘what’s in a name’ in reproductive genetics
- Guerrilla eugenics: gene drives in heritable human genome editing
- Should mitochondrial replacement therapy be funded by the National Health Service?
- Moral reasons to edit the human genome: picking up from the Nuffield report
- Queering the genome: ethical challenges of epigenome editing in same-sex reproduction
- Gender “tailored” conceptions: should the option of embryo gender selection be available to infertile couples undergoing assisted reproductive technology?
- Future of global regulation of human genome editing: a South African perspective on the WHO Draft Governance Framework on Human Genome Editing
- Fear and infertility research
- Comparative ethical evaluation of epigenome editing and genome editing in medicine: first steps and future directions